Clinical trials: Pheochromocytoma/Paraganglioma
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Pheochromocytoma, Paraganglioma
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Pheochromocytomas and paragangliomas (PPGLs) are chromaffin cells-derived tomours that originate from the adrenal medulla (80~85%) and the extra-adrenal sympathetic paraganglia in thorax, abdomen and pelvis (15~20%) or…
- Trial name
- NCT05948137
- Testing
- F-18 FDOPA PET/CT
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Asan Medical Center
Pheochromocytoma, Paraganglioma
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
White adipose tissue (WAT) and brown adipose tissue (BAT) form the main adipose tissue subtypes in humans and several animals. BAT, owing to its unique metabolic function, has been of increased focus and interest in metabolic…
- Trial name
- NCT06440122
- Testing
- FDG-PET Scan
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- King's College Hospital NHS Trust
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05883085
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Hypertension
Omics Signature in the Diagnosis of Hypertension
The purpose of this study is to assess the validity and usefulness of omics signatures for improved identification and risk stratification of patients with endocrine hypertension and stratification of patients with primary…
- Trial name
- ENSAT-HT (NCT02772315)
- Testing
- omics
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 4,000 people
- Sponsor
- Radboud University Medical Center
Paraganglioma, Pheochromocytoma
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer.
- Trial name
- SNIPP (NCT00843037)
- Testing
- Sunitinib
- Where
- 4 sites in Canada, Netherlands
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Paraganglioma, Pheochromocytoma
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late.
- Conditions
- Paraganglioma, Pheochromocytoma, Genetic Predisposition to Disease, Pathology
- Trial name
- PPGL-Pred (NCT04788927)
- Where
- 2 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05885386
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Cancer, Medullary, Carcinoid Tumor
18F-FDOPA PET in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic.
- Conditions
- Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma, Paraganglioma
- Trial name
- NCT02431715
- Testing
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
PGL
Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma Resection
This observational study was conducted in patients undergoing elective laparoscopic pheochromocytoma/paraganglioma(PPGL) resection. It mainly answers the following two main questions: 1.
- Trial name
- MI-PPGL (NCT05752773)
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Peking Union Medical College Hospital
Adrenal Tumor, Primary Aldosteronism
Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
This research aims to establish clinical evidence for optimal treatment guidelines for adrenal diseases using real-world data. The approach involves building prospective and retrospective patient registries, which will be…
- Conditions
- Adrenal Tumor, Primary Aldosteronism, Cushing Syndrome, Pheochromocytoma
- Trial name
- NCT06229405
- Where
- South Korea
- Volunteers
- 8,200 people
- Sponsor
- Seoul National University Hospital
Pheochromocytoma
131MIBG to Treat Malignant Pheochromocytoma
This study will evaluate the effectiveness of 131MIBG in treating malignant pheochromocytoma and whether sensitization medications improve the response to treatment.
- Trial name
- NCT00028106
- Testing
- [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT02592356
- Testing
- Computed Tomography, Dual X-ray Absorptiometry, Physical Examination
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are…
- Trial name
- NCT03649438
- Testing
- 131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Pheochromocytoma, Metastatic, Paraganglioma, Malignant
- Trial name
- NCT04860700
- Testing
- anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal…
- Conditions
- Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma
- Trial name
- NCT06479811
- Testing
- [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytomas, Paragangliomas
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL).
- Trial name
- PRRT-PGL-PHEO (NCT07538791)
- Testing
- Peptide Receptor Radionuclide Therapy (PRRT)
- Where
- 10 sites in Italy
- Volunteers
- 210 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Kidney Cancer, Urologic Malignant Disorders
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.
- Conditions
- Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Familial Renal Cancer (FRC)
- Trial name
- NCT00001238
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Background: Gastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma/paragangliomas (PPGL) are tumors that grow in or near the adrenal glands.
- Conditions
- Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
- Trial name
- NCT06427798
- Testing
- 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)